Study title:
A 12-week randomized, multicenter, double-blind, double-dummy, placebo and active controlled, parallel group study evaluating the safety, efficacy, and pharmacokinetics of Foradil (formoterol fumarate) (10 mg bid) delivered by the multi-dose dry powder in
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Respiratory Tract Diseases
|
Brands: |
MAH holders: Please see report, Please see report |
Assessment: |
Active substance: FORMOTEROL |
ATC code: R03A C13 |
Document link:
|
Document date:
|
Study number: CFOR258F2303 |
EudraCT number:
|
Scope of study: Clinical |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
-
|
-
|